A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy

Giorgio Scagliotti, Makoto Nishio, Miyako Satouchi, Giuseppe Valmadre, Seiji Niho, Domenico Galetta, Diego Cortinovis, Fabio Benedetti, Eiji Yoshihara, Lukas Makris, Akira Inoue, Kaoru Kubota

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences